Form 4: Biote Corp. CFO Reports Stock Option Grant

Biote Corp. Chief Financial Officer Robert Peterson has been granted a stock option for 107,169 shares with an exercise price of $1.43, vesting over time starting April 1, 2027.

Summary

• Robert Charles Peterson, Chief Financial Officer of Biote Corp., was granted an employee stock option on April 1, 2026.
• The option allows for the purchase of 107,169 shares of Class A Common Stock at an exercise price of $1.43 per share.
• Vesting begins on April 1, 2027, with 25% of the shares vesting on that date.
• The remaining shares will vest in 36 substantially equal monthly installments thereafter, contingent on continuous service.
• The option has an expiration date of March 31, 2036.
• This filing is made pursuant to Section 16(a) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard executive compensation disclosure without immediate financial performance indicators or strategic shifts.

Positives

• Grant of stock options to a key executive (CFO) can align management's interests with shareholders.
• The option provides a long-term incentive with a vesting schedule extending over several years.
• The exercise price of $1.43 suggests a potential for future stock price appreciation.

Negatives

• The filing does not provide details on the company's financial performance or strategic initiatives, making it difficult to assess the intrinsic value of the option grant.
• The vesting schedule is contingent on continued employment, which carries inherent risk for the executive.

Risks

• The value of the stock option is directly tied to the future performance and stock price of Biote Corp., which is subject to market volatility and business risks.
• If the company's stock price does not exceed the exercise price of $1.43, the options may not be exercised.
• The executive's continued service is a condition for vesting, meaning any departure before vesting completion would result in forfeiture of unvested options.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's financial performance. The future outlook for the stock option is dependent on the company's future stock price and the continued service of the reporting person.

Management Comments

• The filing is a standard disclosure of a stock option grant to a Section 16 reporting person.
• The Power of Attorney document indicates that Robert Peterson has authorized legal counsel and company representatives to execute filings on his behalf.

Industry Context

StockSavvy.ai notes that the granting of stock options to executives is a common practice in the biotechnology and healthcare sectors, aiming to incentivize performance and retain talent. The specific terms of this grant, including the exercise price and vesting schedule, will be evaluated against industry norms as more financial and operational data for Biote Corp. becomes available.

Stakeholder Impact

• Shareholders: The stock option grant aligns the CFO's incentives with potential stock price appreciation, which can benefit shareholders if the company performs well. However, it also represents potential dilution if options are exercised.
• Employees: This filing does not directly impact other employees, but it reflects the company's compensation strategy for its executive leadership.
• Management: The CFO receives a long-term incentive tied to company performance and continued employment.

Next Steps

• The reporting person must continue to comply with Section 16(a) reporting requirements for any future transactions or changes in beneficial ownership.
• The stock options will vest according to the schedule outlined, contingent on the reporting person's continued service.
• The company's future financial performance will determine the ultimate value and exercise of these options.

Key Dates

Keywords

Biote Corp., BTMD, Form 4, Stock Option, Employee Stock Option, Robert Peterson, CFO, Securities Exchange Act, Beneficial Ownership, Vesting Schedule